The new chief commercial officer will oversee the US launch of Nyxoah’s Genio neurostimulator for obstructive sleep apnea, pending FDA approval.

Summary: Nyxoah SA has appointed Scott Holstine as chief commercial officer to lead the expected US launch of the Genio neurostimulator for obstructive sleep apnea (OSA). The Genio system, which has already received the CE Mark in Europe, is expected to receive FDA approval by the end of the year. Holstine, who brings over 26 years of experience in the medical device industry, will oversee the commercial operations and build a patient-focused team to support the successful launch of Genio in the US.

Key Takeaways:

  • Leadership Appointment: Nyxoah has appointed Scott Holstine as chief commercial officer to spearhead the US launch of the Genio neurostimulator for treating obstructive sleep apnea.
  • Pending FDA Approval: The Genio system, which is already CE-marked in Europe, is expected to receive FDA approval for the US market by the end of 2024.
  • Extensive Experience: Scott Holstine brings over 26 years of experience in the medical device industry, with a strong track record in US product launches and building high-performing commercial teams.

Nyxoah SA, a medical technology company focused on developing solutions to treat obstructive sleep apnea (OSA), has appointed Scott Holstine as chief commercial officer to lead the US launch of the Genio neurostimulator, which the company expects to receive US Food and Drug Administration approval for the treatment of OSA by the end of the year.  

The Genio system received the European CE Mark in 2019.

Scott Holstine Photo credit: Nyxoah

“This is a promising time for patients with OSA. Nyxoah’s strong DREAM study results and Genio’s success in markets outside of the US have demonstrated the potential of Genio’s breakthrough and unique solution,” says Holstine in a release. “Both patients and physicians are eagerly awaiting a second player in the [hypoglossal nerve stimulator] field. I am thrilled to be part of the team building out a patient-focused commercial operation that prioritizes the success of our healthcare provider partners in treating OSA.”

Experience and Background

Holstine brings over 26 years of experience in the medical device industry with a proven track record in US product launches, building and leading commercial organizations trademarked by strong operational execution. 

He graduated with the Superintendent’s Award for Excellence (Star Wreath) from the United States Military Academy at West Point, New York. After serving as a Captain in the US Army, Scott received his MBA from the University of Minnesota, Carlson School of Management – Minneapolis.

“As we expect FDA approval by the end of 2024, the hiring of an experienced commercial leader is instrumental in further accelerating our US go-to-market strategy into a concrete launch execution plan. This starts with having a commercial team fully operational by year-end. Scott is a dynamic and creative leader with countless accomplishments in building high-performing teams and developing new markets for innovative technologies,” says Olivier Taelman, Nyxoah’s chief executive officer, in a release. “This appointment is the kickoff of building a team of world-class patient- and clinician-focused professionals, supporting Nyxoah’s mission to make sleep simple again for OSA patients.”